IRS2 and acute myeloid leukemia: In addition, while we did not identify a specific biomarker using transcriptomic or proteomic approaches (data not shown), phosphoproteomic data from two separate analysis on different primary AML samples subsets showed significantly higher levels of phosphorylated-insulin receptor substrate 2 (IRS2) in sensitive cells (Fig. 4E, F).